Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Reply to Matsui et al.

Leukemia volume 20, page 2042 (2006)Cite this article

I did appreciate the reply letter from Dr Matsui et al.,1 which I believe clarifies most of the issues I had raised in reference to their recent paper.2 However, their reply, which refers to ‘a potential confounding factor in their (our) analysis3 may have come from reliance on the FAB guidelines to accurately diagnose patients’, is still somewhat misleading. Although the presence of a cytogenetic abnormality is useful in confirming a suspected diagnosis of myelodysplastic syndrome (MDS), its present is not mandated by either FAB or WHO 2001 guidelines. The diagnostic criteria for MDS in both classifications largely overlap. Therefore, the assumption that we might have ‘misclassified’ cases because of the use of FAB (the only system available in 1996) is incorrect.

I completely agree with Dr Matsui et al.1 that the enumeration of bone marrow CD34 positive cells should be further tested, possibly in a randomized prospective way, in order to conclusively confirm its validity for separating the two disorders. The fact that the ‘CD34 approach’ has not become standard of practice up to now, I suspect, it is also due to the usual interlaboratory variability which plagues immunohistochemistry laboratories in general. As this is not likely to change in the near future, the best approach to this difficult differential diagnosis remains, in my judgment, a comprehensive one inclusive of morphology, immunohistology, flow cytometry and cytogenetics. Marrow cytogenetics still maintains its major prognostic role in this group of hypoplastic marrow disorders.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Matsui WH, Brodsky RA, Smith BD, Borowitz MJ, Jones RJ . Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia 2006; 20: 458–462.

    Article  CAS  Google Scholar 

  2. Matsui WH, Brodsky RA, Smith BD, Borowitz MJ, Jones RJ . Quantification of marrow CD34 positive cells: an important tool for distinguishing between hypoplastic myelodysplastic syndromes and aplastic anema. In: Orazi A (ed). Leukemia 2006; in press.

  3. Orazi A, Albitar M, Heerema NA, Haskins S, Neiman RS . Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anemia by CD34 and PCNA immunostaining of bone marrow biopsy specimens. Am J Clin Pathol 1997; 107: 268–274.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Division of Hematopathology, Clarian Pathology Laboratory (CPL), Indiana University School of Medicine, Indianapolis, IN, USA

    A Orazi

Authors
  1. A Orazi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Orazi, A. Reply to Matsui et al.. Leukemia 20, 2042 (2006). https://doi.org/10.1038/sj.leu.2404395

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404395

Search

Advanced search

Quick links